IN2012DE00912A - - Google Patents

Download PDF

Info

Publication number
IN2012DE00912A
IN2012DE00912A IN912DE2012A IN2012DE00912A IN 2012DE00912 A IN2012DE00912 A IN 2012DE00912A IN 912DE2012 A IN912DE2012 A IN 912DE2012A IN 2012DE00912 A IN2012DE00912 A IN 2012DE00912A
Authority
IN
India
Prior art keywords
stable
antioxidants
free
amino acids
chelating agents
Prior art date
Application number
Other languages
English (en)
Inventor
Dhiraj Khattar
Rajesh Khanna
Mukti Yuadav
Krishanu Burman
Original Assignee
Fresenius Kabi Oncology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Oncology Ltd filed Critical Fresenius Kabi Oncology Ltd
Priority to IN912DE2012 priority Critical patent/IN2012DE00912A/en
Priority to PCT/IB2013/052356 priority patent/WO2013144814A1/en
Priority to US14/387,670 priority patent/US20150073000A1/en
Publication of IN2012DE00912A publication Critical patent/IN2012DE00912A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14Details; Accessories therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN912DE2012 2012-03-27 2013-03-25 IN2012DE00912A (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IN912DE2012 IN2012DE00912A (de) 2012-03-27 2013-03-25
PCT/IB2013/052356 WO2013144814A1 (en) 2012-03-27 2013-03-25 Stable ready-to-use pharmaceutical composition of pemetrexed
US14/387,670 US20150073000A1 (en) 2012-03-27 2013-03-25 Stable ready-to-use pharmaceutical composition of pemetrexed

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN912DE2012 IN2012DE00912A (de) 2012-03-27 2013-03-25

Publications (1)

Publication Number Publication Date
IN2012DE00912A true IN2012DE00912A (de) 2015-09-11

Family

ID=48095972

Family Applications (1)

Application Number Title Priority Date Filing Date
IN912DE2012 IN2012DE00912A (de) 2012-03-27 2013-03-25

Country Status (3)

Country Link
US (1) US20150073000A1 (de)
IN (1) IN2012DE00912A (de)
WO (1) WO2013144814A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2680832B1 (de) 2011-03-04 2019-09-04 Grünenthal GmbH Wässrige pharmazeutische formulierung von tapentadol zur oralen verabreichung
KR101703980B1 (ko) * 2013-12-30 2017-02-08 주식회사 삼양바이오팜 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법
PT3206666T (pt) 2014-10-16 2020-03-11 Synthon Bv Composição farmacêutica líquida compreendendo pemetrexedo
DK3256133T3 (da) * 2015-02-13 2022-10-24 Sun Pharmaceutical Ind Ltd Intravenøs infusionsdoseringsform
WO2016151365A1 (en) * 2015-03-26 2016-09-29 Ftf Pharma Private Limited Pharmaceutical composition of pemetrexed
MX2017012312A (es) 2015-03-27 2018-01-18 Gruenenthal Gmbh Formulacion estable para administracion parenteral de tapentadol.
WO2017020048A1 (en) * 2015-07-30 2017-02-02 Expression Pathology, Inc. QUANTIFYING FR-α AND GART PROTEINS FOR OPTIMAL CANCER THERAPY
US20170239250A1 (en) 2016-02-19 2017-08-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
IL301291A (en) * 2016-02-19 2023-05-01 Eagle Pharmaceuticals Inc Pemetrexed formulations
JP6957233B2 (ja) * 2016-06-27 2021-11-02 サン ファーマシューティカル インダストリーズ リミテッドSun Pharmaceutical Industries Ltd. ペメトレキセドの安定な注射溶液
KR20190057349A (ko) 2016-09-23 2019-05-28 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여용 안정한 제제
CN109906071A (zh) 2017-10-10 2019-06-18 太阳制药工业公司 培美曲塞的静脉输注剂型

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
EP1161589B1 (de) 1999-03-16 2003-07-23 Kao Corporation Flüssiges deodorant
US6686365B2 (en) 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
JP2013540104A (ja) 2010-07-28 2013-10-31 イーグル・ファーマシューティカルズ・インコーポレーテッド 延長された保存安定性を有するペメトレキセドを含有する医薬組成物
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법

Also Published As

Publication number Publication date
WO2013144814A1 (en) 2013-10-03
US20150073000A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
IN2012DE00912A (de)
JOP20180103B1 (ar) التركيب الصيدلاني للكاربيتوسين
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2015010971A (es) Derivado novedoso de pirazol.
IN2014DN10386A (de)
MY163083A (en) Solid forms of a pharmaceutically active substance
MX2020003096A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
IN2014DN10670A (de)
MX362879B (es) Usos novedosos.
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
IN2014MN02236A (de)
IN2013MU03641A (de)
PH12016500497A1 (en) Compositions for the treatment of hypertension and/or fibrosis
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
PH12015501386A1 (en) Tricyclic compounds
MX2015012318A (es) Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
MY195384A (en) Two-Component Composition
PH12015502706B1 (en) Oral formulation for the treatment of cardiovascular diseases
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
MX2015016490A (es) Esteres sulfatados de acidos oligohidroxicarboxilicos, y uso de los mismos.
IN2015DN02109A (de)
EP3132797A4 (de) Verwendung einer zusammensetzung mit eisen-(ii)-aminosäurechelat bei der herstellung eines arzneimittels zur linderung von diabetes
IN2013MU03317A (de)